Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]
News [12581]
Articles [170]
Editorials [5]
Conferences [246]
elearning [17]
Additional treatment options impact first-line treatment of mRCC: No
Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, Paris, France
Additional treatment options impact first-line treatment of mRCC: No ( Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, Paris, France )
23 Sep 2014
Current treatment options in mRCC
Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA
Current treatment options in mRCC ( Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA )
23 Sep 2014
Discussion: Additional treatment options impact first-line treatment of mRCC
Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán
Discussion: Additional treatment options impact first-line treatment of mRCC ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )
23 Sep 2014
Additional treatment options impact first-line treatment of mRCC: Yes
Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium
Additional treatment options impact first-line treatment of mRCC: Yes ( Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )
23 Sep 2014
What have we learned? Expert perspectives
Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán
What have we learned? Expert perspectives ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )
23 Sep 2014
From clinical trial to clinical practice: Evidence from the real world
Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid...
From clinical trial to clinical practice: Evidence from the real world ( Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid, Madrid, Spain )
23 Sep 2014
The evolving treatment landscape for HER2-positive metastatic breast cancer
Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium
The evolving treatment landscape for HER2-positive metastatic breast cancer ( Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium )
18 Sep 2014
Navigating current treatment options for HER2-positive MBC: Patient journey 1
Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria
Navigating current treatment options for HER2-positive MBC: Patient journey 1 ( Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria )
18 Sep 2014
ecancermedicalscience editor's choice for September 2014
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for September 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
18 Sep 2014
Overview of skin cancer treatments, past, present and future
Prof John Hawk - President of the World Congress on Cancers of the Skin 2014
Overview of skin cancer treatments, past, present and future ( Prof John Hawk - President of the World Congress on Cancers of the Skin 2014 )
11 Sep 2014
The importance of the World Congress on Cancers of the Skin
Prof John Hawk - President of the World Congress on Cancers of the Skin 2014
The importance of the World Congress on Cancers of the Skin ( Prof John Hawk - President of the World Congress on Cancers of the Skin 2014 )
11 Sep 2014
Moles on the skin increase skin cancer risk
Dr Eugene Ong - University of Oxford, Oxford, UK
Moles on the skin increase skin cancer risk ( Dr Eugene Ong - University of Oxford, Oxford, UK )
11 Sep 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation